-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mosunetuzumab in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mosunetuzumab in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mosunetuzumab in Refractory Chronic Lymphocytic Leukemia (CLL) Drug...
-
Sector Analysis
NewQatar Defense Market Size, Trends, Budget Allocation, Regulations, Acquisitions, Competitive Landscape and Forecast to 2029
Qatar Defense Market Report Overview In 2024, Qatar's defense budget is worth $14.4 billion. The country’s defense budget will grow at a CAGR of more than 6% during 2025-2029. The arms race in the Middle East region, modernization initiatives, the threat of Iranian missiles, and Qatar's diplomatic disputes are driving arms procurement in the country. Additionally, Qatar is spending billions of dollars to increase its military power, especially its air force capabilities. Amidst the ongoing diplomatic crisis, the country had...
-
Sector Analysis
NewArgentina Defense Market Size, Trends, Budget Allocation, Regulations, Acquisitions, Competitive Landscape and Forecast to 2029
Argentina Defense Market Report Overview In 2024, Argentina’s defense budget is worth $919.7 million. The country’s defense budget will grow at a CAGR of less than 1% during 2025-2029. The following are some of the key highlights of the Argentina defense market: The turbulence in the Argentine economy has affected Argentina’s ability to spend on its armed forces. India and Argentina have agreed to firm up ties while simultaneously agreeing to increase engagement in defense and trade. Argentina is focused...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IBB-0979 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IBB-0979 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IBB-0979 in Solid Tumor Drug Details: IBB-0979 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Noraramtide in Multiple Myeloma (Kahler Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Noraramtide in Multiple Myeloma (Kahler Disease) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Noraramtide in Multiple Myeloma (Kahler Disease) Drug Details: Noraramtide...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GEN-3017 in T-Cell Lymphomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GEN-3017 in T-Cell Lymphomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GEN-3017 in T-Cell Lymphomas Drug Details: GEN-3017 (DuoBody-CD3xCD30) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JWTCR-001 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JWTCR-001 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. JWTCR-001 in Solid Tumor Drug Details: Gene therapy is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GEN-3017 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GEN-3017 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GEN-3017 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IAP-0971 in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IAP-0971 in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IAP-0971 in Head And Neck Squamous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IAP-0971 in Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IAP-0971 in Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IAP-0971 in Lung Cancer Drug Details: IAP-0971 is under development for...